METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS
A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
1 - 30 . (canceled)
31 . A method for the treatment of a Flaviviridae infection in a host, comprising administering to said host an anti-virally effective amount of a β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
32 . The method of claim 31 , wherein an anti-virally effective amount of a β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable ester thereof is administered.
33 . The method of claim 32 , wherein the nucleoside is a pyrimidine nucleoside.
34 . The method of claim 33 , wherein the β-D-2′-methyl-ribofuranosyl pyrimidine nucleoside is administered in combination or alternation with a second anti-Flaviviridae agent.
35 . The method of claim 34 , wherein the second anti-Flaviviridae agent is an interferon.
36 . The method of claim 34 , wherein the second anti-Flaviviridae agent is ribavirin.
37 . The method of claim 34 , wherein the second anti-Flaviviridae agent is an interferon, ribavirin, or a combination thereof.
38 . The method of claim 31 , wherein the nucleoside is a pyrimidine nucleoside.
39 . The method of claim 38 , wherein the β-D-2′-methyl-ribofuranosyl pyrimidine nucleoside is administered in combination or alternation with a second anti-Flaviviridae agent.
40 . The method of claim 39 , wherein the second anti-Flaviviridae agent is an interferon.
41 . The method of claim 39 , wherein the second anti-Flaviviridae agent is ribavirin.
42 . The method of claim 39 , wherein the second anti-Flaviviridae agent is an interferon, ribavirin, or a combination thereof.
43 . The method of claim 31 , wherein the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof is in a tablet or capsule.
44 . The method of claim 31 , wherein a unit dose of the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof is administered.
45 . The method of claim 43 , wherein the tablet or capsule contains 50 to 1000 mg of the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
46 . The method of claim 44 , wherein the unit dose contains 50 to 1000 mg of the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
47 . The method of claim 31 , wherein the nucleoside is a β-D-2′-methyl-2′-halo-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
48 . The method of claim 47 , wherein an anti-virally effective amount of a β-D-2′-methyl-2′-halo-ribofuranosyl nucleoside, or a phosphate thereof, or a pharmaceutically acceptable ester thereof is administered.
49 . The method of claim 48 , wherein the nucleoside is a β-D-2′-methyl-2′-halo-ribofuranosyl pyrimidine nucleoside.
50 . A method for the treatment of a Flaviviridae infection in a host, comprising administering to the host an anti-virally effective amount of a compound of Formula XI:
or a pharmaceutically acceptable salt or ester thereof;
wherein:
Base is a pyrimidine base;
R 1 and R 2 are each independently H or phosphate;
R 6 is alkyl;
R 7 is halo; and
X is O.
51 . The method of claim 50 , wherein Base is uracil.
52 . The method of claim 51 , wherein R 6 is methyl.
53 . The method of claim 52 , wherein R 1 is phosphate.
54 . The method of claim 53 , wherein R 2 is H.
55 . The method of claim 50 , wherein the compound of Formula XI is administered in combination or alternation with a second anti-Flaviviridae agent.
56 . The method of claim 55 , wherein the second anti-Flaviviridae agent is an interferon.
57 . The method of claim 55 , wherein the second anti-Flaviviridae agent is ribavirin.
58 . The method of claim 55 , wherein the second anti-Flaviviridae agent is an interferon, ribavirin, or a combination thereof
59 . The method of claim 54 , wherein the compound of Formula XI is administered in combination or alternation with a second anti-Flaviviridae agent.
60 . The method of claim 59 , wherein the second anti-Flaviviridae agent is an interferon, ribavirin or a combination thereof.